Page 594«..1020..593594595596..600610..»

Category Archives: Transhuman News

Keanu Reeves Says He’d Be Cool With Fans Having Sex With Him in VR – Futurism

Posted: December 13, 2021 at 2:17 am

What is Keanu Reeves planning to do with VR? The Other Blue Pill

The Matrix is everywhere. Even in video games.

Later this month, the fourth installment in Matrix series hits theaters. The Matrix Resurrections isnt a reboot, and will seemingly bring back stars Keanu Reeves as Neo and Carrie-Anne Moss as Trinity. Before you see the movie in theaters, though, fans can play a surprise open-world game called The Matrix Awakens: An Unreal Engine 5 Experience.

According to Kotaku, its more of an immersive experience than a playable game. All told, it sounds a fun exploration of virtual worlds and whats really real, which are classic topics from the Matrix franchise.

And riffing on that topic in a video interview with the Verge, the affable Reeves even went as far as to say that hed be open to VR porn in which fans could have sex with him without really having sex with him, of course.

Think of how much money is in porn, Reeves said in the interview.You wouldnt even have to be there, and people could have digital sex with your digital avatar.

Moss, however, was not on board.

I, on the other hand, say no thank you, Moss laughed.

Could we see raunchy, digitally-created porn with Reeves in the future? Well have to wait and see, but we know Reeves is likely to come up with some wild content since he already holds a bit of crypto, has a VR headset and is fascinated by VR storytelling and the Metaverse.

The real world is almost ahead of our science fiction, Reeves said in the video. Wow.

More on the Metaverse: AR Pioneer Warns that Metaverse Could Make Reality Dissapear

Care about supporting clean energy adoption? Find out how much money (and planet!) you could save by switching to solar power at UnderstandSolar.com. By signing up through this link, Futurism.com may receive a small commission.

Link:
Keanu Reeves Says He'd Be Cool With Fans Having Sex With Him in VR - Futurism

Posted in Futurism | Comments Off on Keanu Reeves Says He’d Be Cool With Fans Having Sex With Him in VR – Futurism

Scientists Are Building a "Black Box" to Record the End of Civilization – Futurism

Posted: at 2:17 am

"Its built to outlive us all."Apocalypse Cam

If or when human civilization collapses, what will remain? Maybe parts of some cities. Or the Statue of Liberty, a la Planet of the Apes. Overall, though, there might not be a lot of evidence left behind about what humanity accomplished or what resulted in its downfall.

One team of researchers wants to change that. Their solution? A massive, indestructible box thatll record scientific data to give future civilizations insight on how exactly humanity fell.

The project, dubbed Earths Black Box, will be an immense steel monolith installed in a remote location in Tasmania. Its akin to the black boxes that are designed to survive airplane crashes and provide investigators valuable data on what led to the disaster except on a planetary scale.

The project is a collaboration between researchers at the University of Tasmania, marketing agency Clemenger BBDO, and creative agency The Glue Society.

The team is designing the box to record climate data such as atmospheric CO2 levels, sea temperatures, and energy consumption levels. Itll also gather contextual information like news headlines and social media posts.

The idea is if the Earth does crash as a result of climate change, this indestructible recording device will be there for whoevers left to learn from that, Jim Curtis, the executive creative director at Clemenger BBDO, told the Australian Broadcasting Corporation (ABC).

The box itself will be made from three-inch-thick steel and cantilevered off granite. Inside will be a system of Internet-connected storage drives powered by solar panels on the boxs roof.

Its built to outlive us all, Jonathan Kneebone, cofounder of the Glue Society, told ABC. If the worst does happen, just because the power grids go down, this thing will still be there.

The biggest issue for the team now is how to help future civilizations access the information it contains. After all, theyll just find a mysterious monolith out in the middle of nowhere and we know how that worked out for us already.

READ MORE: Earth is getting a black box to record our climate change actions, and its already started listening [Australia Broadcasting Corporation]

More on doomsday boxes: Oreo Built a Doomsday Vault to Protect Its Cookies from a Harmless Asteroid

Care about supporting clean energy adoption? Find out how much money (and planet!) you could save by switching to solar power at UnderstandSolar.com. By signing up through this link, Futurism.com may receive a small commission.

See the original post here:
Scientists Are Building a "Black Box" to Record the End of Civilization - Futurism

Posted in Futurism | Comments Off on Scientists Are Building a "Black Box" to Record the End of Civilization – Futurism

DeepMind Says Its New AI Has Almost the Reading Comprehension of a High Schooler – Futurism

Posted: at 2:17 am

Alphabets AI research company DeepMind has released the next generation of its language model,and it says that it has close to the reading comprehension of a high schooler a startling claim.

It says the language model, called Gopher, was able to significantly improve its reading comprehension by ingesting massive repositories of texts online.

DeepMind boasts that its algorithm, an ultra-large language model, has 280 billion parameters, which are a measure of size and complexity. That means it falls somewhere between OpenAIs GPT-3 (175 billion parameters) and Microsoft and NVIDIAs Megatron, which features 530 billion parameters, The Verge points out.

Such a system could allow us to safely and efficiently to summarize information, provide expert advice and follow instructions via natural language, according to a statement.

In a test, the model was able to score highly enough on a high school reading comprehension test to approach human-level performance, according to DeepMinds paper. Its math and reasoning skills, however, left something to be desired, showing less of an improvement.

The more parameters, the more accurate, generally speaking. But there are other issues, like reading comprehension or perpetuating harmful stereotypes, that are proving more difficult to overcome, despite the models sheer size.

Algorithms like Gopher have been used in the past for commercial products like digital assistants and translators. In a test, Gopher was able to have a full dialogue with a human with a surprising level of coherence, according to DeepMind.

But DeepMind isnt looking to commercialize its algorithm.

Thats not the focus right now, Koray Kavukcuoglo, DeepMinds vice president of research,told Fortune.

In an attempt to get ahead of criticism that its algorithm regurgitated ethnic or gender stereotypes often a product of the texts these algorithms were fed DeepMind published an accompanying paper about the steps researchers took to maintain ethical integrity.

For instance, the team built a tool called Retrieval-Enhanced Transformer, a massive two trillion word database to cross-reference its sources.

But even then, the DeepMind team admitted that research on how language models perpetuate harmful stereotypes is still in early stages.

As AI tools become better and better at interpreting text, researchers are increasingly turning to stickier problems, like the potential for spreading misinformation or propaganda.

Even with all the texts on the internet, helping language models like Gopher read between the lines is proving much harder than many AI researchers like to admit.

READ MORE: DeepMind debuts massive language A.I. that approaches human-level reading comprehension [Fortune]

More on AI tools: Researchers Create Narc Neural Network to Help Cops Predict New Designer Drugs

Care about supporting clean energy adoption? Find out how much money (and planet!) you could save by switching to solar power at UnderstandSolar.com. By signing up through this link, Futurism.com may receive a small commission.

Read the rest here:
DeepMind Says Its New AI Has Almost the Reading Comprehension of a High Schooler - Futurism

Posted in Futurism | Comments Off on DeepMind Says Its New AI Has Almost the Reading Comprehension of a High Schooler – Futurism

Scientists Say They Caught China Successfully Changing the Weather – Futurism

Posted: at 2:17 am

China has succeeded in literally changing the weather, a new study claims.

As the South China Morning Post reports, researchers say that during the Chinese Communist Partys centennial celebration over the summer, weather authorities successfully modified the weather above Beijing to clear the sky and reduce pollution for the tens of thousands gathered for a commemorative ceremony in Tiananmen Square.

They did so using cloud seeding technology, a long-studied but controversial process that involves shooting silver iodide particles into the clouds, with the idea of attracting water droplets to modify the weather.

The paper, by researchers at Chinas Tsinghua University, comes a year after reports that China was dramatically expanding its weather modification program to a test area of a whopping 5.5 million square miles by the year 2025. As Futurism noted last December, thats bigger than the entire country of India, and could end up raising serious issues with Chinas neighbors.

Though this isnt the first time China has used cloud-seeding technology its been dabbling since as early as the months leading up to the 2008 Beijing Olympics this appears to be both one of the most successful and also largest-scale tests conducted not just by the CCP, but in the world.

It was also not publicized, and part of the Tsinghua researchers paper focused on the evidence they found that cloud seeding had actually taken place, which included eyewitness reports of rockets being launched into the sky from the mountains outside of of Beijing before the July 1 centennial, and accounts of rocket debris after the fact.

According to theSCMP, there were a number of hurdles that weather officials had to jump to have successfully changed the weather. Pollution leading up to the CCP centennial was especially bad, the report noted, and it was Chinas wettest recorded summer as well. Nevertheless, reports indicated that Beijings pollution on July 1 went from moderate to good, and the mid-day rain did in fact appear to be artificial.

Though areas of the United States and other countries have tried to use cloud seeding technology to change the weather, professional China-worriers have expressed concern that the CCP may use it for nefarious military ends even though the US military has been trying to make it rain since at least 1967.

This successful and large-scale operation in Beijing does, however, raise important questions both about potential military usage of the tech. If one country is able to control its own weather, it could in theory do so elsewhere which is unwelcome news for anyone who isnt invested in forever wars.

Moreover, while cloud seeding is often touted as a potential solution for the megadroughts of the not-so-distant-future, the technology hasnt been successful for long enough to measure how it affects natural weather patterns, nevermind its impact on climate change.

For now, though, lets just marvel at the fact that it now seems possible to literally make it rain on command.

READ MORE: China modified the weather as Communist Party marked centenary in Beijing [South China Morning Post]

More on cloud seeding:A Bunch of US States Are Now Using Weather Modification Technology

Care about supporting clean energy adoption? Find out how much money (and planet!) you could save by switching to solar power at UnderstandSolar.com. By signing up through this link, Futurism.com may receive a small commission.

See the original post:
Scientists Say They Caught China Successfully Changing the Weather - Futurism

Posted in Futurism | Comments Off on Scientists Say They Caught China Successfully Changing the Weather – Futurism

The Head of the CIA Says It’s Been Doing Mysterious Cryptocurrency Work – Futurism

Posted: at 2:17 am

The feds are looking intro cryptocurrencies, and apparently have been since the Trump administration.

This revelation came during the Wall Street Journals uberhyped CEO Summit on Monday, whereasVicereported, CIA Director William Burns admitted that his agency has a number of different projects focused on cryptocurrency.

He went on to say that he inherited the agencys crypto maneuvers from his predecessor, a likely reference to the ghoulish Gina Haspel, who was the last to lead the CIA during Donald Trumps presidency.

My predecessor had started this, but had set in motion a number of different projects focused on cryptocurrency and trying to look at second- and third-order consequences as well and helping with our colleagues in other parts of the U.S. government to provide solid intelligence on what were seeing as well, Burns said.

Translation: the CIA is surveilling crypto networks and platforms, and trying to figure out how important a priority it is for so-called national security.

Burns fedspeak admission came in response to an audience question about the growing problem of ransomware attacks, which are an admittedly very real and serious threat that partially led to a real-life gas shortage,the alleged death of a newborn infant, and possibly even issues with the US beef supply chain.

Crypto, Burns said, could have enormous impact on the heists because one of the ways of getting at ransomware attacks and deterring them is to be able to get at the financial networks that so many of those criminal networks use and that gets right at the issue of digital currencies as well.

AsVice noted, Burns, ahem, cryptic remarks have reinvigorated blockchain bro rumors that Bitcoins mysterious creator Satoshi Nakamoto was an intelligence asset, though asVice noted, that line is mostly just a meme.

While it will likely remain unclear what exactly the CIA and other alphabet soup intelligence agencies are looking at with regards to crypto, this admission is stunning if for no other reason than that its yet another example of a normally-cagey government agency confirming longstanding rumors about its work after years of a steady declassification drip from the Defense Department confirming the existence of UFOs.

Indeed, former CIA acting director Michael Morrell said back in April that the blockchain is a boon for surveillance in a white paper meant to encourage governments to embrace crypto.

We probably wont know for decades what the CIA and its fellow intelligence agencies are up to with crypto, but at least we now know that theyre up tosomething.

READ MORE: The CIA Is Deep Into Cryptocurrency, Director Reveals [Vice]

More on government and crypto:The U.S. Government Has Held Over $1 Billion in Seized Cryptocurrency

Care about supporting clean energy adoption? Find out how much money (and planet!) you could save by switching to solar power at UnderstandSolar.com. By signing up through this link, Futurism.com may receive a small commission.

Continued here:
The Head of the CIA Says It's Been Doing Mysterious Cryptocurrency Work - Futurism

Posted in Futurism | Comments Off on The Head of the CIA Says It’s Been Doing Mysterious Cryptocurrency Work – Futurism

MIT Scientist Says We’re on the Brink of a Mass Extinction Event – Futurism

Posted: at 2:17 am

Hes been talking about it for years now but nobodys listening.Inching Toward Extinction

Theres no question things are a bit dire right now when it comes to climate change but there is some good news: a Massachusetts Institute of Technology (MIT) scientist says were on the brink of mass extinction.

Wait, no. Thats horrible news.

Daniel Rothman, a professor of geophysics at MIT, has spoken about his predictions of a new mass extinction event in the past. He reiterated his Cassandran concerns in a recent interview with The Times of Israel, saying that human disruptions to the carbon cycle will ultimately result in calamity.

Every time there has been a major event in the history of life, there has also been a major perturbation of the environment, Rothamn told the newspaper. These things tend to come together.

Rothman reached his conclusions by observing past mass extinction events, during which there was an increased rate in carbon cycle change. In short, he says, theres only so much carbon that can be injected into the atmosphere and oceans in a geological time frame before we reach an extinction-level tipping point.

For example, according to his calculations, the threshold for carbon in the ocean is roughly 300 gigatons which is disconcerting because humans are on track to add up to 500 gigatons of carbons into the oceans by 2100. In his analysis, that puts the Earth squarely on the path towards a mass extinction event.

Luckily, there is some hope. Global leaders are beginning to take the issue of climate change more seriously than ever before. International efforts such as the recent UN Climate Change Conference are a big step in the right direction.And there have already been some rudimentary steps toward geoengineering.

Still, theres a lot more that countries can and should be doing to deal with the greatest existential threat of our time.

Its, I think, frankly a more difficult problem than the sort of stuff I work on because Im just trying to figure out what the truth is, Rothman told the newspaper. One would like to see more but good people are doing their best.

READ MORE: Headed for a sixth mass extinction? MIT geophysicist warns oceans are on the brink [The Times of Israel]

More on extinction: Scientist Says That Humans Are Almost Certainly Going Extinct

Care about supporting clean energy adoption? Find out how much money (and planet!) you could save by switching to solar power at UnderstandSolar.com. By signing up through this link, Futurism.com may receive a small commission.

Continue reading here:
MIT Scientist Says We're on the Brink of a Mass Extinction Event - Futurism

Posted in Futurism | Comments Off on MIT Scientist Says We’re on the Brink of a Mass Extinction Event – Futurism

Elon Musk Just Sold His Final Home to Live in a Small Prefab Box – Futurism

Posted: at 2:17 am

Looks like he's already packing his bags for Mars.No Homes

Tesla CEO Elon Musk has officially sold off his last remaining home, for a cool $30 million. That means his only official abode is a small, $50,000 prefab hes renting at his space companys headquarters near Boca Chica, Texas.

Back in June, Musk tweeted that hed decided to sell my last remaining house. Just needs to go to a large family who will live there.

Its a special place, he added.

Initially, he put the house, a massive California mansion that used to belong to Gene Wilder, on sale for $37.5 million which turned out a little steep, even for the one percent. He tried again with a different agent in October, Insider reports,where itfinally sold.

Musk is,ostensibly, fully committed to building a city on Mars. And that means he needs cash and lots of it. Earlier this year, Musk said that hewas selling almost all physical possessions, in an effort to devote myself to Mars and Earth.

His plans couldnt be more ambitious.The concept is for afleet of 1,000 Starship spacecraft to populate a Martian metropolis with one million people by the year 2050.

Musk is looking to invest heavily in the venture himself.And even if real estate is only a tiny piece of that pie, its something.

I want to be able to contribute as much as possible to the city on Mars, he told Mathias Dpfner, the CEO of Axel Springer, last year. That means just a lot of capital.

READ MORE: Elon Musk sold a San Francisco mansion, which was his last remaining home, for $30 million [Insider]

More on Elon: Elon Musk Says That Immortality Tech Would Be Very Dangerous

Care about supporting clean energy adoption? Find out how much money (and planet!) you could save by switching to solar power at UnderstandSolar.com. By signing up through this link, Futurism.com may receive a small commission.

Continued here:
Elon Musk Just Sold His Final Home to Live in a Small Prefab Box - Futurism

Posted in Futurism | Comments Off on Elon Musk Just Sold His Final Home to Live in a Small Prefab Box – Futurism

What Is The Best Bath Bomb For People With Eczema? – The List

Posted: at 2:09 am

It's easy to assume that eczema and bath bombs don't work well together, but that isn't actually the case. The right bath bomb can not only make you feel more relaxed, but it can also help to soothe your skin and prevent your eczema from getting worse. When selecting bath products including bath bombs for eczema-prone skin, It's An Itchy Little World recommends avoiding bath bombs that use preservatives, artificial coloring, and scents as they can cause irritation and trigger an eczema flare-up.

When treating skin that is prone to eczema, it's important to ensure that you are using products that contain the most natural ingredients possible. As per Byrdie, one of the best bath bombs for eczema-prone skin is Eczema Honey Oatmeal Bath Bomb ($8.95) from Eczema Honey Co. This bath bomb helps to calm and soothe eczema thanks to the oatmeal and honey that form a large part of the formula. According to the Eczema Honey Co website, this bath bomb is designed to offer a calming and soothing bath that will give eczema-prone skin all of the moisture and nutrients it craves.

Lushbath bombs also tend to also be suitable for eczema-prone skin, due to being made from all-natural ingredients. One of the most comforting bath bombs is the Black Rose($8.95), which has rose oil to calm the skin and Sicilian lemon oil to uplift it.

More here:
What Is The Best Bath Bomb For People With Eczema? - The List

Posted in Eczema | Comments Off on What Is The Best Bath Bomb For People With Eczema? – The List

European Commission Approves Pfizer’s Cibinqo (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis – Pfizer

Posted: at 2:09 am

Cibinqo is a once-daily oral treatment with proven efficacy demonstrated in a large-scale clinical trial program

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved the 100 mg and 200 mg doses of Cibinqo (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. Additionally, a 50 mg dose was approved to treat moderate-to-severe AD specifically in patients with moderate and severe renal impairment (kidney failure) or certain patients receiving treatment with inhibitors of cytochrome P450 (CYP) 2C19.

For adults living with moderate-to-severe atopic dermatitis, Cibinqo could help provide relief from the hallmark symptom of intense itch and has demonstrated rapid improvements in skin clearance, extent, and severity of disease, versus placebo, said Dr. Stephan Weidinger, Professor of Dermatology at Christian-Albrechts University Kiel and Vice Head of the Department of Dermatology at the University Hospital Schleswig-Holstein, Kiel, Germany. The approval of Cibinqo in the European Union makes me hopeful for many patients who will have this additional option to help manage the often painful and disruptive symptoms of moderate-to-severe atopic dermatitis.

The approval of Cibinqo was based on the results of five clinical studies of more than 2,800 patients including four Phase 3 studies and an ongoing long-term open label extension study. Cibinqo demonstrated meaningful improvements across measures of symptom relief and disease control versus placebo. In one trial including an active control arm with dupilumab, which evaluated patients on background topical medicated therapy, Cibinqo 200 mg was associated with a greater improvement in itch relief after two weeks than dupilumab. Cibinqo also demonstrated a consistent safety profile across trials, including in a long-term extension study, showing a favorable benefit-risk profile.

There have been few treatment innovations over the last decade for those in the European Union suffering with the daily discomfort, distress, and pain caused by moderate-to-severe atopic dermatitis, said Mike Gladstone, Global President of Pfizer Inflammation & Immunology. The safety and efficacy established through a rigorous clinical trial program, designed to evaluate measures of symptom relief most important to patients, gives us great confidence in the positive impact Cibinqo could have on those living with this debilitating immuno-inflammatory condition.

The most common adverse events reported with Cibinqo in 5% of patients were nausea (15.1%) and headache (7.9%). The most frequent serious adverse reactions were infections (0.3%).

Additional Details on the Cibinqo Clinical Trial Program

Findings from the following five studies in the Cibinqo JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program were included in the submission to support this approval. The trials evaluated measures of improvements for AD including the Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI), and Peak Pruritus Numerical Rating Scale (PP-NRS):

Select findings for Cibinqo 100 mg, 200 mg, and placebo follow. P-value differences versus placebo across endpoints in JADE MONO-1, JADE MONO-2, and JADE COMPARE were *p<0.01 or **p<0.001. Treatment effects in subgroups, such as age or weight, were consistent with the results in the overall study populations.

About Cibinqo (abrocitinib)

Cibinqo is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. Inhibition of JAK1 is thought to modulate multiple cytokines involved in pathophysiology of atopic dermatitis, including interleukin IL-4, IL-13, IL-31, IL-22, and thymic stromal lymphopoietin (TSLP).

Cibinqo received marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA), the Japanese Ministry of Health, Labour and Welfare (MHLW) and Koreas Ministry of Food and Drug Safety (MFDS) earlier this year.

About Atopic Dermatitis

AD is a chronic inflammatory skin disease characterized by dry skin, intense itching and recurrent relapsing eczematous lesions with a heterogeneous clinical presentation. AD lesions are characterized by erythema (skin turning red or purple depending on normal skin color), induration (hardening)/papulation (formulation of papules), lichenification, oozing/crusting.i,ii,iii

AD affects up to 10% of adults worldwide.iv The prevalence of AD in adults in Europe is approximately 5-10%.v,vi Approximately 1 in 3 adults with AD have moderate-to-severe disease.vii,viii

About Pfizer Inflammation & Immunology

At Pfizer Inflammation & Immunology, we strive to deliver breakthroughs that enable freedom from day-to-day suffering for people living with autoimmune and chronic inflammatory diseases, which can be debilitating, disfiguring and distressing, dramatically affecting what they can do. With a focus on immuno-inflammatory conditions in Rheumatology, Gastroenterology and Medical Dermatology, our current portfolio of approved medicines and investigational molecules spans multiple action and delivery mechanisms, from topicals to small molecules, biologics and biosimilars. The root cause of many immunological diseases is immuno-inflammation, which requires specifically designed agents. Our differentiated R&D approach resulted in one of the broadest pipelines in the industry, where we purposefully match molecules to diseases where we believe they can make the biggest difference. Building on our decades-long commitment and pioneering science, we continue to advance the standard of care for patients living with immuno-inflammatory diseases and are working hand-in-hand with patients, caregivers and the broader healthcare community on healthcare solutions for the many challenges of managing chronic inflammatory diseases, allowing patients to live their best lives.

Pfizer Inc.: Breakthroughs That Change Patients Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at http://www.Pfizer.com. In addition, to learn more, please visit us on http://www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice

The information contained in this release is as of December 10, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Cibinqo (abrocitinib), including its potential benefits and an approval by the European Commission, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications may be filed in any other jurisdictions for any potential indication for Cibinqo; whether and when the application for Cibinqo pending with the U.S. Food and Drug Administration may be approved and whether and when any such other applications that may be pending or filed for Cibinqo may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether Cibinqo will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Cibinqo; uncertainties regarding the commercial or other impact of the results of Janus kinase (JAK) inhibitor studies and data and actions by regulatory authorities based on analysis of such studies and data, which will depend, in part, on benefit-risk assessments and labeling determinations; uncertainties regarding the impact of COVID-19 on our business, operations, and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizers Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned Risk Factors and Forward-Looking Information and Factors That May Affect Future Results, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at http://www.sec.gov and http://www.pfizer.com.

i Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020 Aug 1;396(10247):345-360. doi: 10.1016/S0140-6736(20)31286-1. Erratum in: Lancet. 2020 Sep 12;396(10253):758.

ii Wollenberg et al. European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020 Dec;34(12):2717-2744.

iii Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018 Apr;27(4):340-357.

iv Oszukowska M, Michalak I, Gutfreund K, et al. Role of primary and secondary prevention in atopic dermatitis. Postep Derm Alergol. 2015:32(6):409-420.

v J. Silverberg, A. Wollenberg, A. Egeberg, et al. Worldwide prevalence and severity of Atopic Dermatitis. Poster presented at EADV 2018 Annual Meeting. Paris, France.

vi Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018;73(6):1284-1293. doi:10.1111/all.13401.

vii Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018;73(6):1284-1293. doi:10.1111/all.13401.

viii Mathiesen SM, Thomsen SF. The prevalence of atopic dermatitis in adults: systematic review on population studies. Dermatol Online J. 2019 Aug 15;25(8):13030/qt6nj0x5k0.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211210005319/en/

Media Relations+44 (0) 1737 332 335[emailprotected]

Investor Relations:+1 (212) 733-4848[emailprotected]

Source: Pfizer Inc.

Original post:
European Commission Approves Pfizer's Cibinqo (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis - Pfizer

Posted in Eczema | Comments Off on European Commission Approves Pfizer’s Cibinqo (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis – Pfizer

Tessera Therapeutics Adds New Executives to its Leadership Team as the Company Continues to Pioneer Gene Writing Technology as New Category in Genetic…

Posted: at 2:08 am

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicine known as Gene Writing technology, today announced the expansion of its executive leadership team with appointments of Michael Holmes, Ph.D., Chief Scientific Officer, Iain McFadyen, Ph.D., Chief Data Officer, and Becky Lillie, Chief Human Resources Officer. Jacob Rubens, Ph.D., Co-Founder of Tessera and Senior Principal, Flagship Pioneering, has transitioned from Tesseras Chief Scientific Officer to Chief Innovation Officer. In addition to the three executive appointments, Rebecca Wais, Ph.D., JD, Vice President, Intellectual Property and Legal Affairs, and Ian OReilly, Vice President, Head of GMP Quality, recently joined the Tessera team to bolster the companys internal legal and manufacturing capabilities.

Michael, Iain, and Bec are invaluable additions to our Tessera team and our mission to cure disease by writing in the code of life, said Dr. Geoffrey von Maltzahn, CEO and Co-Founder of Tessera and General Partner, Flagship Pioneering. Their leadership, experiences, and mindsets will be critical in helping to realize our aspirations in genetic medicine, attract and maintain the best talent, and develop our pipeline of Gene Writer candidates to cure and prevent severe diseases.

We set out to revolutionize the field of genetic medicine by pioneering Gene Writing technology that can unlock the therapeutic potential of engineering DNA and address the short-comings of todays gene therapy and gene editing approaches, said Dr. Jacob Rubens. To realize this goal, were building the fields top team across all levels and functions of our organization. Were thrilled that our research will be led by Mike Holmes, whose previous roles included spearheading development of the industrys first gene editing platform and therapeutic candidates.

Michael Holmes, Ph.D., Chief Scientific Officer Dr. Michael Holmes has joined Tessera Therapeutics as its Chief Scientific Officer to lead the development of novel technologies and transformative therapies. Dr. Holmes has more than 20 years of experience working on the development and clinical translation of genome editing- and gene therapy-based approaches. He has an accomplished track record of translating genome engineering technologies to product candidates as evidenced by leading ten therapeutic programs across ex vivo and in vivo therapies. Prior to joining Tessera, Dr. Holmes was the Chief Scientific Officer of Ambys Medicines, and he also held various leadership positions at Sangamo Therapeutics, Inc., including Senior Vice President and Chief Technology Officer.

Dr. Holmes led the efforts that resulted in the first ever clinical candidate of a genome editing-based therapy and has extensive experience in the genome editing of T-cells, hematopoietic stem cells, and hepatocytes. He was also responsible for the research efforts to develop the SB-525 human factor 8 protein (hFVIII) cDNA program, which achieved the highest ever reported level of hFVIII in animal studies and is currently being evaluated in a Phase III study for hemophilia A.

Dr. Holmes holds a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. He also has a B.S. in Molecular Biology from the University of California, San Diego. To date, Dr. Holmes has authored more than 60 publications in the field of genome editing and gene regulation and he is listed as an inventor on more than 40 issued and pending U.S. patents.

After working in the field of genetic medicine for more than 20 years, I was inspired by the capabilities and performance of Tesseras Gene Writer candidates and their potential to fundamentally reshape the field of genetic medicine, said Dr. Holmes. Our Gene Writer tools can make single base pair changes, insertions and deletions, and write entire genes, each with meaningful advantages over current tools, and without reliance upon viral vectors. I look forward to working with the incredible team to advance our Gene Writing platform and to develop win-state medicines that can transform the lives of patients.

Iain McFadyen, Ph.D., Chief Data Officer Dr. Iain McFadyen serves as Chief Data Officer to help advance Tesseras goal of developing potentially curative medicines across multiple therapeutic areas. Previously, Dr. McFadyen held executive and senior leadership positions at LifeMine Therapeutics and Moderna, Inc., respectively. As Chief Data Officer at LifeMine, Dr. McFadyen oversaw the development of the genomic search-based drug discovery platform, led the growth of the Data Sciences department as well as built a fully integrated informatics platform, and led target identification validation efforts. At Moderna, he founded, built, and led the Computational Sciences department, which included people working in data science, and helped develop the platform that delivered mRNA and lipid nanoparticles to patients in the form of the coronavirus vaccine. Throughout his career, Dr. McFadyen has worked in computational biology, computational chemistry, data science, and machine learning/artificial intelligence. He has experience working across various modalities (including mRNA, proteins, and vaccines) and scientific areas that he will apply to his work at Tessera.

"I was drawn to Tessera because I believe Gene Writing technology is the future of medicine, said Dr. McFadyen. Ive previously developed industrial computational platforms for engineering RNA and for discovering genes with unique functions, and I am thrilled to leverage this experience towards creating and optimizing our Gene Writing platform at Tessera.

Dr. McFadyen earned his Ph.D. in Pharmacology from Loughborough University (UK) and the University of Michigan in the Traynor Lab, later serving as a Postdoctoral Research Associate at the University of Minnesota. He received his B.S. in Medicinal and Pharmaceutical Chemistry from Loughborough University. Dr. McFadyen is the author of 21 publications and the inventor on eight patents and patent families with 16 patent applications pending.

Becky Lillie, Chief Human Resources Officer Becky Lillie joins Tessera as the Chief Human Resources Officer to lead the HR function and oversee talent management strategies and incentives to enable the business strategy. Previously, Ms. Lillie served as the Chief Human Experience Officer at Alexion Pharmaceuticals, Inc., where she modernized HR, IT, and Patient Advocacy departments. As a seasoned human capital strategist with over 25 years of experience in the pharmaceutical industry, Ms. Lillie has deep expertise in designing and executing human-centered organizations, operating models, and corporate governance structures.

In todays quickly evolving and highly competitive biotech industry, its more important than ever to demonstrate strong leadership and to build an employee environment that fosters innovative growth and development, said Ms. Lillie. I look forward to working with Tessera to continue building a robust team of scientists motivated by the challenge of developing a new category of genetic medicines to change how we approach disease.

During her career, Ms. Lille progressed through the ranks at Alexion from Executive Director through to Chief Human Experience Officer over several years, modernizing its HR operation and revamping the R&D operating model in the process. She also held leadership positions in R&D at AstraZeneca and Pfizer Inc. Ms. Lillie earned her B.A. in Communications with an emphasis in Public Relations from the University of North Dakota in Grand Forks.

About Tesseras Gene Writer Tools Tesseras Gene Writer tools are based on natures genome architects, Mobile Genetic Elements (MGEs)the most abundant class of genes across the tree of life, representing approximately half of the human genome. Tessera has evaluated tens of thousands of natural and synthetic MGEs to create Gene Writer candidates with the ability to write therapeutic messages into the human genome. Tesseras research engine further optimizes the discovered Gene Writer candidates for efficiency, specificity, and fidelityessentially compressing eons of evolution into a few months.

About Tessera Therapeutics Tessera Therapeutics is pioneering Gene Writing technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The Gene Writing platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. For more information about Tessera, please visit http://www.tesseratherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005310/en/

Visit link:
Tessera Therapeutics Adds New Executives to its Leadership Team as the Company Continues to Pioneer Gene Writing Technology as New Category in Genetic...

Posted in Gene Medicine | Comments Off on Tessera Therapeutics Adds New Executives to its Leadership Team as the Company Continues to Pioneer Gene Writing Technology as New Category in Genetic…

Page 594«..1020..593594595596..600610..»